A recent study using exploratory proteomic analysis in SMA type 1 patients showed that cathepsin D (CTSD), a lysosomal aspartyl protease, was down-regulated following nusinersen treatment, a change that was statistically significant only in responders in a larger sample [26]. The gene discussed is CTSD; the disease is spinal muscular atrophy, type 1.